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4.7–5–7.4. There is therefore a signiﬁcant risk of daytime
somnolence among spouses of patients with severe BPH.
CONCLUSION: As it is known that somnolence is
responsible for a third of all road accidents, it is essential
for these patients to limit the severity of their pathology
by undergoing appropriate treatment.
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OBJECTIVE: An epidemiological study on migraine was
conducted in France in 2000. This general population
study—GRIM 2000—was among others designed to eval-
uate the socio-economic impact of migraine.
METHODS: In a sample of 10,585 subjects over the age
of 15 years, representative of the French population,
1,486 people suffering from headache were interviewed.
Part of the questionnaire concerned consumption of
medical resources and loss of productivity.
RESULTS: 880 of the 1,486 subjects complaining of
headache were found to suffer from migraine (according
to IHS criteria 1-1, 1-2, and 1-7). Migraine patients had
consulted their general practitioner an average of three
times during the previous 6 months. Seventy percent of
these patients systematically took medication to relieve
their headache and they also reported that they always
took the same treatment. The medications most fre-
quently (90%) used were analgesics and non-steroidal
anti-inﬂammatory drugs. 4% of migraine patients took
triptans. 8% of migraineurs took a prophylactic treat-
ment for their headaches. The complementary investiga-
tions most frequently performed were ophthalmic
examinations (16%). Only seven subjects had been hos-
pitalised for their migraine attacks during the previous 6
months, with an average length of stay of 2.3 days.
Migraine patients were absent from work twice as often
as non-migraine headache patients, with an average of 6
days of absence during the previous 3 months. Finally, a
strong correlation was observed between severity of the
attack and consumption of medical resources (particu-
larly medications and visits to the doctor).
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OBJECTIVES: X-rays are frequently used as the initial
imaging study for low back pain (LBP). X-rays are inex-
pensive, but neither sensitive nor speciﬁc for many causes
of LBP. Recently developed rapid magnetic resonance
(RMR) imaging protocols provide more accurate anat-
omical information. Furthermore, because of reduced
imaging time, RMR cost may approach that of X-ray. We
conducted a randomized controlled trial measuring the
societal perspective cost-effectiveness of RMR versus 
X-ray for patients with LBP.
METHODS: Patients with lumbar x-rays ordered in 
one of four clinical centers were eligible. Consenting 
subjects were randomized to X-ray or RMR. The primary
outcome was functional status (Roland scale) at 12
months. Economic outcomes included time trade-off
(TTO), visual analogue scale (VAS), and SF-36 derived
utility. Costs of RMR and X-ray imaging were deter-
mined in time-motion studies. Other health care and non-
health care costs were measured using medical record
review and questionnaires and valued using standard unit
costs.
RESULTS: 380 patients were randomized. Functional
outcomes and cost data were available for 328 (86%) and
362 (95%) patients respectively. At 12 months the mean
function of both groups had improved, but there was no
difference between groups (X-ray 4.0 versus RMR 3.9; 
p = 0.939). Likewise, there was no effect on VAS or SF-
36 derived utilities. RMR patients had greater improve-
ment in TTO scores (10.9 versus 3.2; p = 0.026). Health
care costs following RMR were higher with borderline
signiﬁcance ($2154 versus $1638; p = 0.075), principally
due to more specialist consultations and surgery. X-ray
dominated RMR in the primary analysis.
CONCLUSIONS: Our results suggest that the extra cost
of RMR does not result in improved functional status and
currently it should not replace X-ray in clinical practice.
Given the poor correlation between TTO and other 
outcomes, the difference in TTO outcomes is probably a
spurious ﬁnding but warrants further study.
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